Intensive Care Medicine
Gastroenterology
Hepatology
High Evidence

Hepatic Failure Pathology

Acute liver failure (ALF) is defined as severe hepatic dysfunction with coagulopathy (INR ≥1.5) and encephalopathy in a patient without pre-existing liver disease, developing within 26 weeks of symptom onset....

51 min read

Clinical board

A visual summary of the highest-yield teaching signals on this page.

Urgent signals

Safety-critical features pulled from the topic metadata.

  • INR >6.5 in paracetamol ALF indicates severe hepatocyte loss
  • Grade III-IV encephalopathy with cerebral oedema risk - requires ICP monitoring
  • Lactate >3.5 mmol/L after resuscitation predicts poor prognosis
  • Arterial ammonia >150 μmol/L associated with cerebral herniation risk

Exam focus

Current exam surfaces linked to this topic.

  • CICM First Part Written SAQ
  • CICM First Part Written MCQ
  • CICM First Part Viva

Editorial and exam context

CICM First Part Written SAQ
CICM First Part Written MCQ
CICM First Part Viva
Clinical reference article

Hepatic Failure Pathology

Quick Answer

Clinical Note

Acute liver failure (ALF) is defined as severe hepatic dysfunction with coagulopathy (INR ≥1.5) and encephalopathy in a patient without pre-existing liver disease, developing within 26 weeks of symptom onset. Classification by timing: hyperacute (<7 days), acute (7-21 days), subacute (21 days - 26 weeks). Paracetamol toxicity is the leading cause in Australia (50-60%), causing centrilobular (Zone 3) hepatocyte necrosis via NAPQI-mediated glutathione depletion and oxidative stress. Multi-organ dysfunction includes coagulopathy (reduced synthesis of factors II, VII, IX, X but ALSO anticoagulants - creating "rebalanced haemostasis"), hepatic encephalopathy (ammonia → glutamine → astrocyte swelling), cerebral oedema (cytotoxic mechanism with herniation risk), hyperdynamic circulation (low SVR), hepatorenal syndrome (Type 1 - rapidly progressive), and immune dysfunction (SIRS response with infection susceptibility). King's College Criteria guide transplant listing.

CICM Exam Focus

Clinical Note

SAQ Topics (First Part Written)

  • Define acute liver failure and classify by temporal onset pattern
  • Describe the mechanism of paracetamol hepatotoxicity including NAPQI formation and zonality
  • Explain the pathophysiology of hepatic encephalopathy including ammonia metabolism
  • Describe the coagulation abnormalities in ALF and the concept of "rebalanced haemostasis"
  • Explain the mechanisms of cerebral oedema in acute liver failure
  • Describe the pathophysiology of hepatorenal syndrome

Viva Topics

  • Hepatocyte death pathways: necrosis vs apoptosis in ALF
  • Metabolic derangements in ALF (hypoglycaemia, lactate, electrolytes)
  • Haemodynamic changes in liver failure: hyperdynamic circulation
  • Immune dysfunction and SIRS in ALF
  • Prognostic scoring: King's College Criteria and MELD
  • Hepatic regeneration mechanisms

Common Examiner Questions

  • "Explain why Zone 3 is preferentially affected in paracetamol toxicity"
  • "Why might bleeding be less of a problem than expected in ALF despite high INR?"
  • "Describe the pathophysiology linking hyperammonaemia to cerebral oedema"
  • "What are the mechanisms of renal failure in hepatorenal syndrome?"
  • "How does ALF cause immune dysfunction and increase infection risk?"

Key Points

Clinical Note

Acute liver failure (ALF) requires: (1) Coagulopathy (INR ≥1.5), (2) Hepatic encephalopathy, (3) No pre-existing cirrhosis, (4) Illness duration <26 weeks. O'Grady classification: Hyperacute (<7 days - best prognosis), Acute (7-21 days), Subacute (21 days - 26 weeks - worst prognosis with transplant-free survival).

Clinical Note

CYP2E1/CYP1A2 convert paracetamol to NAPQI (N-acetyl-p-benzoquinone imine). NAPQI is normally conjugated by glutathione. In overdose, glutathione depletion allows NAPQI to bind covalently to cellular proteins, causing mitochondrial dysfunction, oxidative stress, and hepatocyte death predominantly in Zone 3 (centrilobular) due to highest CYP2E1 concentration.

Clinical Note

Zone 3 (centrilobular, perivenular) is most susceptible to paracetamol, hypoxia, and many toxins due to: lowest oxygen tension, highest CYP450 concentration, lowest glutathione levels. Zone 1 (periportal) is preferentially damaged by phosphorus poisoning and some viral hepatitides. Bridging necrosis connects portal and central areas.

Clinical Note

ALF reduces synthesis of BOTH procoagulant factors (II, VII, IX, X, fibrinogen) AND anticoagulants (Protein C, Protein S, Antithrombin). The INR only measures procoagulants. In practice, haemostasis is often "rebalanced"

  • patients may not bleed excessively despite markedly elevated INR. However, the balance is precarious and can tip toward thrombosis or haemorrhage.
Clinical Note

Ammonia (from gut bacteria, GI bleeding, renal production) accumulates due to impaired hepatic conversion to urea. In astrocytes, ammonia combines with glutamate to form glutamine (via glutamine synthetase), which is osmotically active, causing astrocyte swelling. Additional mechanisms: neuroinflammation, GABA-ergic tone, false neurotransmitters, manganese accumulation.

Clinical Note

Unlike chronic liver disease, ALF causes significant cerebral oedema primarily through CYTOTOXIC mechanism (astrocyte swelling from glutamine accumulation). The blood-brain barrier remains largely intact. Ammonia >150 μmol/L and Grade III-IV encephalopathy are major risk factors. Cerebral oedema can cause intracranial hypertension and herniation (20-25% of ALF deaths).

Clinical Note

HRS represents functional renal failure due to: (1) Splanchnic vasodilation (NO, prostacyclin) causing relative hypovolemia, (2) Compensatory RAAS and SNS activation causing renal vasoconstriction, (3) Reduced effective circulating volume. Type 1 HRS: rapidly progressive (creatinine doubles in <2 weeks); Type 2: slowly progressive (associated with refractory ascites).

Clinical Note

ALF causes systemic vasodilation (reduced SVR to 800-1200 dyn·s/cm⁵) with compensatory increased cardiac output (hyperdynamic state). Mechanisms: increased NO production (iNOS upregulation), prostaglandins, endotoxemia from gut translocation. Similar to sepsis physiology. Portal hypertension develops acutely due to hepatic sinusoidal disruption.

Clinical Note

ALF causes paradoxical immune dysfunction despite SIRS response: reduced complement, impaired Kupffer cell function, decreased opsonisation, neutrophil dysfunction. SIRS criteria met in 50-60% of ALF. Infection occurs in 50-80% of patients. Common organisms: Staphylococcus, Streptococcus, enteric Gram-negatives, Candida.

Clinical Note

For paracetamol ALF: pH <7.30 after resuscitation OR (INR >6.5 AND creatinine >300 μmol/L AND Grade III-IV encephalopathy). For non-paracetamol ALF: INR >6.5 OR any 3 of: age <10 or >40, non-A non-B hepatitis/drug reaction, jaundice >7 days before encephalopathy, INR >3.5, bilirubin >300 μmol/L. Positive predictive value ~90% for transplant requirement.


Definition and Classification

Acute Liver Failure: Definition

Acute liver failure (ALF) is defined by the presence of (PMID: 21757548):

Clinical Note

Essential Features:

  1. Coagulopathy: INR ≥1.5 (or PT ≥15 seconds)
  2. Hepatic encephalopathy: Any grade (I-IV)
  3. No pre-existing chronic liver disease: Exceptions - acute Wilson's disease, reactivation of hepatitis B, autoimmune hepatitis flare
  4. Illness duration: <26 weeks from onset of symptoms

Key Distinction: Acute-on-chronic liver failure (ACLF) describes decompensation of pre-existing cirrhosis and has different pathophysiology and management.

Temporal Classification (O'Grady Classification)

The O'Grady classification (1993) stratifies ALF by jaundice-to-encephalopathy interval (PMID: 8242296):

ClassificationJaundice to EncephalopathyTypical CausesCerebral Oedema RiskTransplant-Free Survival
Hyperacute<7 daysParacetamol, hepatitis A/B, ischaemicHIGH (↑↑)Best (36-55%)
Acute7-21 daysHepatitis B, drug reactionsModerate (↑)Intermediate (7-15%)
Subacute21 days - 26 weeksDrug reactions, seronegative hepatitisLower (↓)Worst (7-14%)
Clinical Pearl

Hyperacute liver failure (especially paracetamol) has the HIGHEST cerebral oedema risk but the BEST transplant-free survival if the patient survives the acute phase. This reflects the liver's remarkable regenerative capacity following a single massive insult. Subacute failure has ongoing hepatocyte destruction outpacing regeneration, leading to poorer outcomes.

Alternative Classification: AASLD/ALFSG

The US Acute Liver Failure Study Group uses slightly different terminology (PMID: 21757548):

CategoryJaundice to Encephalopathy
Acute liver failure<26 weeks
Fulminant hepatic failure<8 weeks
Subfulminant hepatic failure8-26 weeks

Aetiology of Acute Liver Failure

Overview of Causes

Clinical Note

Australia/New Zealand:

  • Paracetamol: 50-60% (leading cause)
  • Drug-induced (non-paracetamol): 10-15%
  • Viral hepatitis: 10-15%
  • Indeterminate: 10-15%
  • Other: 5-10%

Developing World:

  • Viral hepatitis (A, B, E): 40-50%
  • Indeterminate: 20-30%
  • Drug-induced: 10-15%

Paracetamol (Acetaminophen) Hepatotoxicity

Paracetamol is the most common cause of ALF in Australia, UK, and USA (PMID: 18768945).

Single Acute Overdose vs Staggered Overdose

PatternDefinitionNAC ProtocolPrognosis
Single acute ingestionAll tablets within 1 hourRumack-Matthew nomogram applicableGenerally better
Staggered overdoseMultiple supra-therapeutic doses over >1 hourNomogram NOT applicable; treat based on clinical findingsOften worse - delayed presentation

Risk Factors for Hepatotoxicity

Patient Factors (reduced glutathione):

  • Chronic alcohol use (CYP2E1 induction, glutathione depletion)
  • Malnutrition, fasting (depleted glycogen and glutathione)
  • Enzyme-inducing medications (phenytoin, carbamazepine, rifampicin)
  • Chronic liver disease

Dose Factors:

  • Acute ingestion >150 mg/kg (adults) or >200 mg/kg (children) concerning
  • 7.5 g in adults considered potentially hepatotoxic

  • Therapeutic misadventure often involves multiple products containing paracetamol

Viral Hepatitis

VirusALF FrequencyEpidemiologySpecial Features
Hepatitis A<1% of HAV infectionsFaecal-oral; outbreaks in Indigenous communitiesHigher ALF risk in underlying liver disease
Hepatitis B1-4% of acute HBVParenteral/sexual; higher rates in Indigenous populationsReactivation in immunosuppression can cause ALF
Hepatitis DCo-infection or superinfectionParenteral; requires HBVHigh mortality with superinfection
Hepatitis EUp to 25% in pregnancyFaecal-oral; waterborne; travel-associatedMajor cause in endemic areas; dangerous in pregnancy
Red Flag

Immunosuppression (chemotherapy, rituximab, TNF-α inhibitors, transplantation) can cause HBV reactivation in patients with past infection (HBsAg-negative, anti-HBc positive). Fulminant hepatic failure may occur. All patients should be screened for HBV before immunosuppressive therapy.

Drug-Induced Liver Injury (DILI)

Common culprits in Australia (PMID: 20937949):

Drug/ClassPatternMechanismComments
Anti-tuberculosis (INH, Rifampicin, Pyrazinamide)Hepatocellular or mixedMetabolic, immunoallergicCombination increases risk
Antibiotics (Amoxicillin-clavulanate)Cholestatic or mixedImmunoallergicMost common DILI cause overall
NSAIDsHepatocellularMetabolicDiclofenac, sulindac higher risk
Anticonvulsants (Phenytoin, valproate)HepatocellularMetabolicValproate: mitochondrial toxicity
StatinsHepatocellularIdiosyncraticRare, usually reversible
Herbal/supplementsVariableVariableOften unrecognised; kava, black cohosh, comfrey

Wilson's Disease

An important cause of ALF in young patients (<40 years) (PMID: 18506894):

  • Pathophysiology: ATP7B gene mutation → copper accumulation → oxidative damage, mitochondrial dysfunction
  • Key features: Kayser-Fleischer rings (95% in neurological Wilson's), Coombs-negative haemolytic anaemia (copper release), low serum ceruloplasmin
  • ALF presentation: Often presents with features suggesting haemolysis (low ceruloplasmin, high bilirubin:ALP ratio, Coombs-negative haemolysis)
  • Prognostic scoring: Wilson's Disease Prognostic Index (bilirubin, AST, INR, albumin, WCC) - score ≥11 indicates need for transplant
Clinical Pearl

Suspect Wilson's when ALF occurs with:

  • ALP:bilirubin ratio <4
  • AST:ALT ratio >2.2
  • Coombs-negative haemolytic anaemia
  • Low serum ceruloplasmin (<0.2 g/L)
  • High 24-hour urinary copper (>100 μg)
  • Kayser-Fleischer rings on slit-lamp examination

Wilson's ALF requires urgent transplant listing as spontaneous recovery does not occur.

ConditionTimingFeaturesDelivery Required
Acute fatty liver of pregnancy (AFLP)3rd trimesterHypoglycaemia, DIC, encephalopathy, microvesicular steatosisYes - curative
HELLP syndrome2nd-3rd trimesterHaemolysis, Elevated Liver enzymes, Low PlateletsYes
Hepatic rupture3rd trimester, pre-eclampsiaSudden severe pain, haemodynamic collapseSurgical emergency

AFLP Pathophysiology: Often associated with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency in fetus → accumulation of fatty acid metabolites → maternal hepatotoxicity (PMID: 10515901).

Other Causes

CauseKey Features
Ischaemic (hypoxic) hepatitis"Shock liver"
  • massive AST/ALT elevation (thousands), rapid resolution if perfusion restored | | Budd-Chiari syndrome | Hepatic vein thrombosis; acute presentation can cause ALF | | Mushroom poisoning (Amanita phalloides) | α-amanitin inhibits RNA polymerase II; delayed GI symptoms → hepatic failure | | Autoimmune hepatitis | May present as ALF; responds to corticosteroids in some cases | | Heat stroke | Massive cytokine release, ischaemia, direct thermal injury | | Malignant infiltration | Lymphoma, metastatic breast cancer - rare cause |

Hepatocyte Death Pathways

Overview

Hepatocyte death in ALF occurs through two major pathways: necrosis and apoptosis. The predominant pathway depends on the aetiology and severity of injury (PMID: 23720129).

Necrosis vs Apoptosis

Clinical Note
FeatureNecrosisApoptosis
TriggerSevere, overwhelming injuryControlled signals, moderate injury
Energy requirementATP-independentATP-dependent
MorphologyCell swelling, membrane rupture, karyolysisCell shrinkage, chromatin condensation, apoptotic bodies
InflammationSevere - DAMPs releasedMinimal - "clean" death
ProcessUncontrolled, passiveProgrammed, regulated
Key mediatorsROS, calcium overload, ATP depletionCaspases (3, 7, 8, 9)
Dominant inParacetamol (severe), ischaemiaViral hepatitis, DILI (some), Fas-mediated

Paracetamol-Induced Hepatocyte Death

NAPQI Formation and Toxicity

The mechanism of paracetamol hepatotoxicity is well-characterised (PMID: 23720129, PMID: 25033466):

Step 1: Metabolism

  • 90% of paracetamol: glucuronidation (UGT) and sulfation (SULT) → non-toxic metabolites
  • 5-10%: CYP450 oxidation (primarily CYP2E1, also CYP1A2, CYP3A4) → NAPQI

Step 2: Detoxification

  • NAPQI normally conjugated with glutathione (GSH) → non-toxic mercapturic acid
  • Requires adequate glutathione stores

Step 3: Toxicity (in overdose)

  • Glutathione depleted (typically >70% depletion)
  • Excess NAPQI binds covalently to cellular proteins (especially mitochondrial proteins)
  • Protein adducts disrupt mitochondrial respiration

Step 4: Mitochondrial Dysfunction

  • Inhibition of electron transport chain
  • Decreased ATP production
  • Increased reactive oxygen species (ROS) production
  • Mitochondrial permeability transition pore (mPTP) opening

Step 5: Cell Death

  • ATP depletion → necrosis
  • Cytochrome c release → apoptosis (if ATP sufficient)
  • Release of endonucleases → nuclear DNA fragmentation
  • JNK (c-Jun N-terminal kinase) activation amplifies mitochondrial injury

The Role of JNK (c-Jun N-terminal Kinase)

JNK is a critical amplifier of paracetamol toxicity (PMID: 20673547):

  1. Initial NAPQI-protein adducts cause mitochondrial dysfunction
  2. ROS production activates JNK in cytoplasm
  3. Activated JNK translocates to mitochondria
  4. JNK amplifies ROS production and inhibits electron transport
  5. This creates a positive feedback loop of mitochondrial injury
Clinical Pearl

NAC (N-acetylcysteine) is the antidote for paracetamol toxicity because it:

  1. Replenishes glutathione: Provides cysteine for GSH synthesis (primary mechanism early)
  2. Acts as antioxidant: Directly scavenges ROS
  3. Improves mitochondrial function: Supports respiratory chain (mechanism of late benefit)
  4. Enhances sulfation: Alternative conjugation pathway

NAC is most effective within 8-10 hours but provides benefit even up to 24+ hours post-ingestion through mechanisms beyond GSH repletion.

Zonality of Hepatic Injury

The liver acinus (functional unit) has three zones with different metabolic properties (PMID: 24905494):

ZoneLocationO₂ TensionCYP450 ActivityGlutathioneInjury Pattern
Zone 1PeriportalHighestLowestHighestPhosphorus, iron, some viruses
Zone 2IntermediateModerateIntermediateIntermediateMixed
Zone 3Centrilobular (perivenular)LowestHighest (especially CYP2E1)LowestParacetamol, alcohol, hypoxia, CCl₄

Why Zone 3 is Most Susceptible to Paracetamol

  1. Highest CYP2E1 concentration: More NAPQI generated per hepatocyte
  2. Lowest oxygen tension: Impairs aerobic metabolism when stressed
  3. Lowest glutathione: Less capacity to detoxify NAPQI
  4. Lowest NADPH: Reduced regeneration of glutathione
  5. Centrifugal blood flow: Toxins accumulate as blood flows centrally

Histopathology of Hepatocyte Death

Necrosis Patterns

PatternDescriptionCauses
Centrilobular (Zone 3) necrosisDeath around central vein, sparing portal tractsParacetamol, hypoxia, CCl₄
Periportal (Zone 1) necrosisDeath around portal tractsPhosphorus, eclampsia
Bridging necrosisNecrosis connecting portal-central or portal-portalSevere viral hepatitis, DILI
Massive (panacinar) necrosisConfluent necrosis of entire aciniFulminant ALF (any cause)
Submassive necrosisExtensive but not complete necrosisSevere hepatitis

Microscopic Features of ALF

  • Hepatocyte dropout: Empty spaces where hepatocytes were
  • Collapse of reticulin framework: Architecture destroyed
  • Inflammatory infiltrate: Lymphocytes, macrophages, neutrophils
  • Ductular reaction: Proliferation of biliary epithelium (regenerative response)
  • Cholestasis: Bile plugs in canaliculi
  • Mallory-Denk bodies: May be seen in alcoholic, NASH, some drug injury

Coagulopathy in Acute Liver Failure

Synthesis Failure

The liver synthesises virtually all coagulation factors (except Factor VIII and von Willebrand factor) (PMID: 26070319):

Pro-coagulant Factors Affected

FactorHalf-lifeClinical Significance
Factor VII4-6 hoursShortest half-life; INR rises earliest
Factor II (Prothrombin)60-72 hoursMajor component of PT/INR
Factor V12-24 hoursBoth synthesis and consumption; marker of severity
Factor IX18-24 hoursIntrinsic pathway
Factor X40-60 hoursCommon pathway
Fibrinogen3-5 daysMay be normal or elevated (acute phase response) early
Red Flag

Factor V is synthesised ONLY by the liver and is consumed in DIC. Factor V level <20% correlates with very poor prognosis in ALF. It is used in some prognostic models (Clichy criteria) as it reflects both synthetic function and consumption.

The Concept of "Rebalanced Haemostasis"

Traditional teaching suggested ALF patients have severe bleeding risk due to coagulopathy. However, modern understanding recognises a more complex picture (PMID: 26070319, PMID: 20947927):

Clinical Note

Procoagulant Deficits:

  • Factors II, V, VII, IX, X, XI
  • Fibrinogen (variable)

Anticoagulant Deficits (equally or more reduced):

  • Protein C (half-life 8 hours) - often profoundly reduced
  • Protein S
  • Antithrombin
  • ADAMTS13 (vWF cleaving protease)

Net Effect:

  • INR/PT reflects ONLY procoagulant loss (not anticoagulant loss)
  • Thrombin generation may be NORMAL or even INCREASED
  • Patients are often at risk of THROMBOSIS as well as bleeding
  • The balance is precarious - can tip either way with additional insults

Clinical Implications

  1. INR does not predict bleeding: Standard INR correlates poorly with bleeding risk in ALF
  2. Prophylactic FFP not recommended: Unless bleeding or invasive procedure planned
  3. Thromboelastography (TEG/ROTEM): Better reflects global coagulation status
  4. VTE prophylaxis: May be appropriate despite elevated INR (assess individually)
  5. Avoid vitamin K deficiency: Give vitamin K but don't expect full INR correction

Additional Haemostatic Abnormalities

AbnormalityMechanismClinical Effect
ThrombocytopeniaReduced TPO production, splenic sequestration, consumptionUsually moderate (50-100 × 10⁹/L)
Platelet dysfunctionUremia, NO, prostacyclinProlonged bleeding time
HyperfibrinolysisReduced α2-antiplasmin, reduced PAI-1, increased tPAMay cause bleeding
Reduced plasminogenSynthetic failureImpaired clot lysis
Elevated vWFEndothelial activation, reduced ADAMTS13Pro-thrombotic

Disseminated Intravascular Coagulation

DIC may complicate ALF (PMID: 31327219):

  • Incidence: 20-30% of severe ALF
  • Triggers: Tissue factor release from necrotic hepatocytes, endotoxaemia, sepsis
  • Features: Thrombocytopenia, elevated D-dimer, microangiopathic haemolysis (rare)
  • Management: Treat underlying cause; blood products only for active bleeding

Hepatic Encephalopathy

Definition and Grading

Hepatic encephalopathy (HE) is a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction (PMID: 24866571):

Clinical Note
GradeClinical FeaturesMental Status
Minimal (Covert)Abnormal psychometric testing, no clinical signsNormal on examination
Grade I (Covert)Mild confusion, euphoria or depression, shortened attention span, sleep disturbanceOrientated
Grade II (Overt)Drowsiness, disorientation, inappropriate behaviour, asterixisDisorientated to time
Grade III (Overt)Marked confusion, incoherent speech, sleepy but rousable, gross disorientationDisorientated to time and place
Grade IV (Overt)Coma (unrousable to painful stimuli)Coma

Pathophysiology of Hepatic Encephalopathy

HE is multifactorial but ammonia is central to the pathophysiology (PMID: 25042402):

Ammonia Metabolism

Normal ammonia handling:

  1. Sources: Gut bacteria (urease), enterocyte glutaminase, renal ammoniagenesis, muscle deamination
  2. Absorption: Absorbed from colon into portal circulation
  3. Hepatic clearance: Periportal hepatocytes convert NH₃ to urea (urea cycle) - 85% of ammonia clearance
  4. Alternative pathway: Perivenous hepatocytes convert NH₃ to glutamine (glutamine synthetase)

In liver failure:

  • Reduced hepatocyte mass → impaired urea cycle capacity
  • Porto-systemic shunting → bypasses liver
  • Arterial ammonia levels rise (normal <50 μmol/L; HE often >100 μmol/L)

The Ammonia-Glutamine-Astrocyte Swelling Pathway

This is the key mechanism linking hyperammonaemia to cerebral dysfunction (PMID: 25042402):

  1. Ammonia crosses BBB: NH₃ (un-ionised) freely crosses blood-brain barrier
  2. Astrocyte uptake: Ammonia enters astrocytes
  3. Glutamine synthesis: Glutamine synthetase (in astrocytes) converts glutamate + NH₃ → glutamine
  4. Osmotic effect: Glutamine is osmotically active → astrocyte swelling
  5. Mitochondrial toxicity: Glutamine enters mitochondria → generates ammonia locally → mitochondrial dysfunction
  6. Oxidative stress: ROS generation, impaired energy metabolism
Clinical Pearl

Neurons do not express glutamine synthetase. Astrocytes are the only CNS cells capable of ammonia detoxification, making them the primary target of ammonia toxicity. Astrocyte swelling, a form of cytotoxic oedema, is the hallmark of HE in ALF.

Additional Mechanisms in HE

MechanismContribution
GABA-ergic toneIncreased endogenous benzodiazepine-like substances, increased GABA receptor sensitivity
NeuroinflammationMicroglial activation, cytokine production (synergises with ammonia)
Manganese accumulationNormally excreted in bile; deposits in basal ganglia (T1 MRI hyperintensity)
False neurotransmittersAromatic amino acids (phenylalanine, tyrosine) cross BBB; compete with catecholamine synthesis
Zinc deficiencyZinc is cofactor for urea cycle enzymes; deficiency worsens HE
Altered tryptophan metabolismIncreased serotonin precursors may contribute to altered consciousness

Precipitants of Hepatic Encephalopathy

In ALF, HE develops due to acute hepatocyte loss. In cirrhosis, precipitants should be sought:

PrecipitantMechanism
GI bleedingProtein load → increased ammonia production
ConstipationProlonged colonic transit → more ammonia absorbed
Infection/sepsisCatabolism, neuroinflammation, reduced cerebral perfusion
Electrolyte imbalanceHypokalaemia and metabolic alkalosis favour NH₃ (crosses BBB) over NH₄⁺
DehydrationReduced renal ammonia excretion
Sedatives/opioidsDirect CNS depression; mask HE progression
Dietary protein excessIncreased ammonia substrate (rare cause)
Portosystemic shunt (TIPS)Direct ammonia shunting to systemic circulation

Cerebral Oedema in Acute Liver Failure

Epidemiology and Risk Factors

Cerebral oedema is a major cause of death in ALF, occurring in 20-30% of patients with Grade III-IV HE (PMID: 14714165):

Red Flag

High Risk:

  • Grade III-IV hepatic encephalopathy
  • Arterial ammonia >150-200 μmol/L
  • Hyperacute liver failure (especially paracetamol, hepatitis A/B)
  • Young age
  • Rapidly rising ammonia
  • Need for vasopressors
  • SIRS/infection

Lower Risk:

  • Subacute liver failure
  • Non-paracetamol aetiology (some)
  • Older age

Pathophysiology: Cytotoxic vs Vasogenic Oedema

Cerebral oedema in ALF is predominantly cytotoxic (intracellular), in contrast to many other causes of cerebral oedema (PMID: 25042402):

FeatureCytotoxic Oedema (ALF)Vasogenic Oedema
LocationIntracellular (astrocyte swelling)Extracellular
BBB integrityIntact (early)Disrupted
MechanismGlutamine accumulation, osmotic stressBBB breakdown, plasma extravasation
MRI appearanceRestricted diffusion (DWI bright, ADC dark)T2 hyperintensity, normal diffusion
White vs grey matterGrey matter predominant (astrocyte-rich)White matter predominant

The "Trojan Horse" Hypothesis

Glutamine acts as a "Trojan horse" for ammonia toxicity (PMID: 17428996):

  1. Ammonia is incorporated into glutamine in astrocyte cytoplasm
  2. Glutamine is transported into mitochondria
  3. Mitochondrial glutaminase cleaves glutamine → releases ammonia inside mitochondria
  4. High intra-mitochondrial ammonia → mPTP opening → oxidative stress → mitochondrial dysfunction
  5. This amplifies cellular energy failure and swelling

Intracranial Hypertension and Herniation

Monro-Kellie Doctrine

The skull is a rigid container; its contents (brain ~80%, blood ~10%, CSF ~10%) must remain constant. Cerebral oedema increases brain volume, initially compensated by CSF displacement and reduced venous blood. When compensation is exhausted, ICP rises exponentially.

Clinical Features of Raised ICP

FeatureMechanism
Cushing's responseHypertension + bradycardia + irregular respirations (late sign)
Pupillary changesUnilateral then bilateral dilation (CN III compression)
Decerebrate posturingBrainstem dysfunction
Loss of brainstem reflexesProgressive herniation
Hyperventilation then apnoeaInitially compensatory, then brainstem failure

Cerebral Perfusion Pressure

CPP = MAP - ICP
  • Target CPP: >60 mmHg
  • Target ICP: <25 mmHg (or <20 mmHg in severe cases)
  • Autoregulation often impaired in ALF - CPP-dependent cerebral blood flow

Management of Cerebral Oedema in ALF

Clinical Note

ICP Monitoring (controversial):

  • Consider in Grade III-IV HE with high-risk features
  • Epidural or intraparenchymal (subdural has higher bleeding risk)
  • Coagulopathy correction to INR <1.5 or platelets >50 recommended
  • Limited evidence for mortality benefit but aids management decisions

Therapeutic Interventions:

TierInterventionTarget
GeneralHead elevation 30°, sedation, avoid hyperthermia, avoid hypoxia/hypercapnia, treat seizuresPrevent secondary injury
Tier 1Osmotherapy (mannitol 0.5-1 g/kg or hypertonic saline 3% 2-5 mL/kg)ICP <25, serum Na 145-155
Tier 2Hypothermia (32-35°C) - reduces ammonia production and cerebral metabolismCore temp 33-34°C
Tier 3Barbiturate coma (rarely used), indomethacin (reduces CBF)Last resort
Ammonia-loweringLactulose, rifaximin (limited acute evidence); CRRT for refractory hyperammonaemiaAmmonia <100

Metabolic Derangements

Hypoglycaemia

Hypoglycaemia is a common and dangerous complication of ALF (PMID: 21757548):

Mechanisms

MechanismExplanation
Impaired gluconeogenesisLiver is primary site of gluconeogenesis; hepatocyte loss reduces capacity
Depleted glycogen storesInitial hepatocyte damage depletes stored glycogen
HyperinsulinaemiaReduced hepatic insulin clearance → elevated insulin levels
Increased glucose utilisationHypermetabolic state, sepsis, regenerating hepatocytes

Clinical Implications

  • May be severe, recurrent, and refractory
  • Can cause or worsen encephalopathy
  • Monitor blood glucose every 1-2 hours initially
  • Continuous glucose infusion (10-20% dextrose) often required
  • Target: Blood glucose 6-10 mmol/L

Lactate and Acid-Base Disturbances

Lactic Acidosis in ALF

Lactate elevation in ALF has multiple mechanisms (PMID: 20190714):

  1. Impaired lactate clearance: Liver normally clears 70% of circulating lactate
  2. Increased production: Tissue hypoxia (hyperdynamic shock), SIRS, anaerobic glycolysis
  3. Hypoperfusion: Cardiogenic or distributive shock component

Prognostic significance:

  • Lactate >3.5 mmol/L after resuscitation is a poor prognostic sign
  • Included in modified King's College Criteria
  • Lactate >3.0 mmol/L at 12 hours post-NAC initiation (paracetamol) predicts poor outcome (PMID: 20190714)

Acid-Base Patterns

PatternMechanismWhen Seen
Metabolic acidosis (lactic)Impaired lactate clearance, tissue hypoperfusionSevere ALF, shock
Respiratory alkalosisCentral hyperventilation (ammonia effect on brainstem)Common early finding
Metabolic alkalosisVomiting, NG losses, diureticsVariable
MixedCombination of aboveAdvanced ALF

Electrolyte Disturbances

ElectrolyteAbnormalityMechanism
SodiumHyponatraemiaDilutional (ADH excess), free water retention
PotassiumHypokalaemiaLosses (vomiting, diarrhoea), alkalosis, insulin (glucose)
PhosphateHypophosphataemiaGlucose infusion, refeeding, regeneration (high demand)
MagnesiumHypomagnesaemiaLosses, poor intake
CalciumHypocalcaemiaCitrate (if massive transfusion), hypoalbuminaemia
Clinical Pearl

Phosphate is critical for ATP production and hepatocyte regeneration. Profound hypophosphataemia can limit recovery and is associated with poor prognosis if not corrected. In contrast, rising phosphate levels without replacement may indicate failed regeneration (no phosphate consumption by regenerating cells).


Haemodynamic Changes

Hyperdynamic Circulation

ALF produces a circulatory pattern remarkably similar to sepsis (PMID: 15671025):

Clinical Note
ParameterDirectionTypical Values
Systemic vascular resistance (SVR)↓↓500-1000 dyn·s/cm⁵ (normal 900-1400)
Cardiac output (CO)↑↑Increased 50-100%
Mean arterial pressure (MAP)Often requires vasopressor support
Pulmonary vascular resistanceVariable
Mixed venous O₂ saturation>75% (impaired O₂ extraction)
Oxygen consumption (VO₂)Supply-independent (early) to supply-dependent

Mechanisms of Vasodilation

MediatorSourceEffect
Nitric oxide (NO)iNOS upregulation (endothelium, macrophages)Potent vasodilator
Prostacyclin (PGI₂)EndotheliumVasodilation, platelet inhibition
Endotoxin (LPS)Gut translocation (bacterial)iNOS induction, cytokine release
Cytokines (TNF-α, IL-1, IL-6)Macrophages, hepatocytesVascular dysfunction
Carbon monoxide (CO)Heme oxygenase inductionVasodilation

Portal Hypertension in ALF

Unlike chronic liver disease, portal hypertension in ALF develops acutely (PMID: 21757548):

Mechanisms:

  1. Sinusoidal obstruction: Hepatocyte swelling compresses sinusoids
  2. Regenerative nodule formation: Disrupts normal architecture
  3. Inflammatory infiltration: Adds to sinusoidal resistance
  4. Microvascular thrombosis: DIC component

Consequences (often less pronounced than chronic portal hypertension):

  • Ascites (usually mild)
  • Gut oedema and ileus
  • Contributes to bacterial translocation

Cardiac Dysfunction

Clinical Note

High-output cardiac failure:

  • Hyperdynamic but relative cardiac insufficiency
  • Similar to septic cardiomyopathy

Specific abnormalities:

  • QT prolongation (metabolic, drug effects)
  • Arrhythmias (electrolyte disturbances)
  • Subclinical myocardial depression (circulating depressant factors)

Adrenal insufficiency:

  • Relative adrenal insufficiency common in severe ALF
  • Impaired cortisol response to ACTH
  • Consider stress-dose hydrocortisone in refractory shock

Hepatorenal Syndrome

Definition

Hepatorenal syndrome (HRS) is functional renal failure in patients with advanced liver disease, in the absence of intrinsic renal pathology (PMID: 26254576):

Diagnostic criteria (ICA 2015):

  1. Cirrhosis with ascites OR acute liver failure
  2. Diagnosis of AKI (increase in creatinine ≥26.5 μmol/L within 48 hours or ≥50% within 7 days)
  3. No improvement after 2 days of diuretic withdrawal and albumin expansion (1 g/kg/day, max 100 g/day)
  4. Absence of shock
  5. No current or recent nephrotoxic drugs
  6. No parenchymal kidney disease (proteinuria <500 mg/day, microhaematuria <50 RBCs/hpf, normal renal ultrasound)

Classification

TypeClinical FeaturesPrognosis
HRS-AKI (Type 1)Rapid progression: doubling of creatinine to >226 μmol/L in <2 weeksMedian survival 2 weeks without treatment
HRS-NAKI (Type 2)Slower progression, often stableMedian survival 6 months; usually with refractory ascites

Pathophysiology

The "arterial vasodilation hypothesis" explains HRS development (PMID: 15915323):

Clinical Note

Step 1: Splanchnic Vasodilation

  • Portal hypertension → splanchnic NO and prostacyclin release
  • Splanchnic arterial vasodilation → blood pooling in mesenteric circulation
  • Reduced effective arterial blood volume (EABV)

Step 2: Compensatory Activation

  • Baroreceptors sense reduced EABV
  • Activation of:
    • Renin-angiotensin-aldosterone system (RAAS)
    • Sympathetic nervous system (SNS)
    • Arginine vasopressin (AVP)

Step 3: Renal Vasoconstriction

  • Angiotensin II, noradrenaline, ADH cause renal arterial vasoconstriction
  • Decreased renal blood flow (despite normal kidney structure)
  • Reduced GFR → oliguric renal failure

Step 4: Failure of Compensation

  • Cardiac output eventually fails to compensate for vasodilation
  • Progressive renal hypoperfusion despite maximal vasoconstriction
  • Worsening sodium and water retention → further ascites

HRS in Acute Liver Failure (vs Cirrhosis)

HRS in ALF differs from cirrhotic HRS:

FeatureHRS in ALFHRS in Cirrhosis
Portal hypertensionAcute, less severeChronic, established
AscitesUsually mildUsually prominent
ReversibilityMay reverse with liver recovery/transplantRarely reverses without transplant
PathophysiologySystemic inflammation dominantSplanchnic vasodilation dominant
Additional factorsNephrotoxins (paracetamol metabolites), ATN componentMore purely functional

Differential Diagnosis of AKI in ALF

DiagnosisFeaturesUrinalysisFENa
HRSFunctional, reversible with transplantBland<1%
Pre-renal azotaemiaResponds to volumeBland<1%
ATNOften from paracetamol, hypotension, sepsisGranular casts, tubular cells>2%
Contrast nephropathyPost-contrast exposureBlandVariable
Abdominal compartment syndromeTense ascites, raised IAPBlandVariable

SIRS and Sepsis in Acute Liver Failure

Immune Dysfunction in ALF

ALF causes a complex immune derangement with both hyperinflammation and immunodeficiency (PMID: 22972682):

Clinical Note

Pro-inflammatory (SIRS) features:

  • Elevated TNF-α, IL-1β, IL-6
  • Activated complement
  • SIRS criteria met in 50-60% of ALF patients
  • Systemic endotoxaemia from gut translocation

Immunodeficiency features:

  • Reduced complement synthesis (C3, C4, C5) - liver synthesises most complement
  • Impaired opsonisation
  • Kupffer cell dysfunction
  • Reduced neutrophil chemotaxis and phagocytosis
  • Lymphocyte dysfunction
  • Reduced immunoglobulin production

Clinical consequence: Patients have SIRS-like physiology but are highly susceptible to infection

Infection in ALF

Infection is common (50-80%) and is a major cause of morbidity and mortality (PMID: 22972682):

Common Organisms

SiteCommon Organisms
RespiratoryStaphylococcus aureus, Streptococcus pneumoniae, Gram-negative bacilli
BloodstreamStaphylococcus (lines), enteric Gram-negatives, Candida species
UrinaryEscherichia coli, Klebsiella, Enterococcus
Intra-abdominalEnteric Gram-negatives, Candida

Risk Factors for Infection

  • Grade III-IV encephalopathy
  • Prolonged ICU stay
  • Multiple invasive devices (CVC, IDC, ETT)
  • Renal replacement therapy
  • Paracetamol aetiology (less immunocompromised than other causes)
  • Need for vasopressors

Prophylactic Antibiotics

Clinical Pearl

Controversial practice - no high-quality RCTs

Arguments for:

  • High infection rate (50-80%)
  • Infection worsens prognosis
  • May prevent bacteraemia triggering cytokine storm

Arguments against:

  • Promotes resistance
  • May not improve outcomes
  • Many infections are fungal

Current practice (varies by centre):

  • Some centres use routine prophylaxis (e.g., piperacillin-tazobactam + fluconazole)
  • Others reserve antibiotics for proven/suspected infection
  • Antifungal prophylaxis considered in high-risk cases

Surveillance cultures (respiratory, urine, blood) recommended every 48-72 hours.

Sepsis Mimicry

ALF can mimic sepsis clinically, making infection diagnosis challenging:

FeatureALF without InfectionSepsis
FeverCommon (necrosis-related)Common
LeukocytosisCommonCommon
Elevated PCTMay be elevatedTypically elevated
LactateOften elevatedOften elevated
Vasopressor needCommonCommon
CulturesNegativePositive (ideally)

Approach: High index of suspicion; low threshold for empiric antibiotics; repeat cultures.


Hepatic Regeneration

Overview of Liver Regeneration

The liver has remarkable regenerative capacity, able to restore original mass after 70% hepatectomy within 2-3 weeks (PMID: 17245125):

Clinical Note

Types of regeneration:

  1. Hepatocyte-driven: Mature hepatocytes proliferate (primary mechanism)
  2. Progenitor cell (oval cell) activation: Hepatic progenitor cells differentiate (when hepatocyte proliferation impaired)

Regeneration vs hyperplasia:

  • True regeneration: Restoration of original structure AND function
  • Liver regeneration is technically "compensatory hyperplasia"
  • remaining hepatocytes enlarge and divide

Hepatocyte Proliferation

Initiation Phase (0-5 hours post-injury)

FactorSourceRole
TNF-αKupffer cells"Priming"
  • makes hepatocytes competent to respond | | IL-6 | Kupffer cells, endothelium | Activates STAT3 → immediate early genes | | Complement (C3a, C5a) | Liver synthesis, activation | Promotes IL-6 release, NF-κB activation | | LPS | Gut (via portal vein) | TLR4 activation → TNF-α release |

Progression Phase (Growth Factors)

Growth FactorSourceMechanism
HGF (Hepatocyte Growth Factor)Stellate cells, endotheliumc-Met receptor → potent mitogen
EGF/TGF-αSalivary glands, macrophagesEGFR → proliferation
VEGFMultipleAngiogenesis to support new tissue
InsulinPancreasMetabolic support, permissive

Termination Phase

FactorMechanism
TGF-βInhibits hepatocyte proliferation
Activin AGrowth arrest
Contact inhibitionCell-cell contact restores quiescence
Restoration of massSignals (unclear) sense adequate regeneration

Progenitor Cell (Oval Cell) Response

When hepatocyte proliferation is impaired (e.g., massive necrosis, chronic injury), hepatic progenitor cells are activated (PMID: 23392622):

Hepatic progenitor cells (HPCs):

  • Location: Canals of Hering (junction of bile canaliculi and bile ducts)
  • Bipotential: Can differentiate into hepatocytes OR cholangiocytes
  • Also called "oval cells" (rodents), "reactive ductular cells" (humans)

Activation signals:

  • Wnt/β-catenin pathway
  • Notch signaling
  • Hedgehog pathway
  • FGF signaling

Ductular reaction: Proliferation of small ductular structures at portal margins - histological evidence of progenitor activation

Factors Affecting Regeneration in ALF

FactorEffect on Regeneration
AgeElderly have reduced regenerative capacity
Nutritional statusMalnutrition impairs regeneration
Infection/sepsisInflammatory cytokines shift from regeneration to acute phase response
Ongoing toxin exposureContinued injury prevents recovery
AetiologyParacetamol (single insult) regenerates better than subacute causes
Haemodynamic stabilityHypoperfusion impairs regeneration
Phosphate levelsHypophosphataemia limits ATP for regeneration
Clinical Pearl

In recovering ALF, serum phosphate typically FALLS as regenerating hepatocytes consume phosphate for ATP synthesis. Persistent hypophosphataemia (requiring replacement) may indicate active regeneration. In contrast, stable or rising phosphate without replacement may suggest failure of regeneration (poor prognosis).


Histopathology

Patterns of Hepatic Necrosis

The histopathological pattern provides aetiological and prognostic information (PMID: 24905494):

Clinical Note
PatternDescriptionCommon Causes
Centrilobular (Zone 3)Necrosis around central veins, periportal sparingParacetamol, hypoxia/ischaemia, heart failure, CCl₄
Periportal (Zone 1)Necrosis around portal tractsPhosphorus poisoning, eclampsia, some drugs
Midzonal (Zone 2)Necrosis in intermediate zone (rare)Yellow fever
Bridging necrosisNecrosis connecting portal-central OR portal-portalSevere viral hepatitis, autoimmune
Panacinar (massive)Complete acinar necrosisFulminant ALF of any cause
SubmassiveExtensive but not complete; some viable hepatocytes remainSevere but potentially recoverable

Microscopic Features

Acute Phase

FeatureDescription
Hepatocyte necrosisEosinophilic cytoplasm, pyknotic nuclei, karyorrhexis
Hepatocyte dropoutEmpty spaces, reticulin collapse
Ballooning degenerationSwollen hepatocytes (pre-necrotic)
Apoptotic bodiesShrunken, eosinophilic cells with fragmented nuclei (Councilman bodies)
CholestasisBile plugs in canaliculi
Inflammatory infiltrateLymphocytes, neutrophils, macrophages
Kupffer cell hyperplasiaActivated Kupffer cells, often containing debris

Regenerative Phase

FeatureDescription
Hepatocyte mitosesDividing hepatocytes
Hepatocyte rosettesRegenerating hepatocytes arranged in circular pattern
Thick cell platesMore than 2-cell-thick plates
Ductular reactionProliferation of ductular structures (progenitor activation)
Nodular regenerationIf survival; may progress to cirrhosis if chronic

Specific Histopathological Patterns by Aetiology

AetiologyCharacteristic Features
ParacetamolCentrilobular confluent necrosis, sharp demarcation from viable tissue
Viral hepatitisSpotty necrosis (scattered), Councilman bodies, portal/lobular inflammation
AutoimmuneInterface hepatitis, plasma cells, "rosettes"
Wilson's diseaseGlycogenated nuclei, copper stains (rhodanine, orcein), Mallory-Denk bodies
AFLPMicrovesicular steatosis, minimal inflammation
Drug-inducedVariable; may have eosinophils, granulomas, cholestasis
IschaemicCentrilobular necrosis with "ghost" hepatocytes, minimal inflammation

Prognostic Scoring

King's College Criteria (1989)

The most widely used criteria for transplant listing in ALF (PMID: 2490426):

Clinical Note

PARACETAMOL-Induced ALF:

  • pH <7.30 after adequate fluid resuscitation (strongest predictor)

OR ALL THREE of:

  • INR >6.5 (or PT >100 seconds)
  • Serum creatinine >300 μmol/L (>3.4 mg/dL)
  • Grade III or IV hepatic encephalopathy

NON-PARACETAMOL ALF:

  • INR >6.5 (or PT >100 seconds) alone

OR ANY THREE of the following:

  • Age <10 or >40 years
  • Aetiology: non-A non-B hepatitis OR idiosyncratic drug reaction
  • Duration of jaundice before encephalopathy >7 days
  • INR >3.5 (or PT >50 seconds)
  • Serum bilirubin >300 μmol/L (>17.5 mg/dL)

Interpretation: Meeting criteria indicates poor prognosis without transplant; consider urgent transplant listing.

Performance of King's College Criteria

MeasureParacetamolNon-Paracetamol
Sensitivity58-69%68-82%
Specificity79-95%76-92%
PPV79-95%73-97%
NPV50-79%81-98%

Limitations:

  • Developed in 1989; medical management has improved
  • Does not account for aetiology-specific factors (e.g., Wilson's)
  • May miss patients who would benefit from transplant

Modified King's College Criteria (with Lactate)

Addition of lactate improves sensitivity for paracetamol ALF (PMID: 20190714):

Lactate criteria:

  • Arterial lactate >3.5 mmol/L after early fluid resuscitation (4 hours) OR
  • Arterial lactate >3.0 mmol/L after full fluid resuscitation (12 hours)

MELD Score (Model for End-Stage Liver Disease)

Originally developed for cirrhosis, MELD is also used in ALF (PMID: 11172350):

MELD = 3.78 \times \ln(bilirubin) + 11.2 \times \ln(INR) + 9.57 \times \ln(creatinine) + 6.43

Bilirubin and creatinine in mg/dL; minimum values 1.0

MELD Score3-Month Mortality
<101.9%
10-196%
20-2919.6%
30-3952.6%
≥4071.3%

In ALF: MELD may be comparable to King's criteria for prognosis; used for transplant allocation in many jurisdictions.

Other Prognostic Markers

MarkerSignificance
Factor V <20%Very poor prognosis (Clichy criteria)
Ammonia >200 μmol/LHigh risk of cerebral oedema and death
Phosphate rising (without replacement)Failure of regeneration
APACHE II/IIIGeneral severity score; validated in ALF
α-fetoprotein (AFP) risingMay indicate hepatocyte regeneration (favourable)
Gc-globulin (vitamin D binding protein)Low levels predict poor outcome

Australian/New Zealand Context

ALF Epidemiology in Australia

Clinical Note

Incidence: Approximately 250 cases of ALF annually in Australia

Aetiology Distribution:

  • Paracetamol: 50-60%
  • Drug-induced (non-paracetamol): 10-15%
  • Viral hepatitis: 10-15%
  • Indeterminate: 10-15%
  • Other (Wilson's, autoimmune, vascular): 5-10%

Liver Transplant Centres:

  • Royal Prince Alfred Hospital (NSW)
  • Austin Hospital (VIC)
  • Princess Alexandra Hospital (QLD)
  • Sir Charles Gairdner Hospital (WA)
  • Flinders Medical Centre (SA)

New Zealand:

  • Auckland City Hospital (only NZ liver transplant centre)

Paracetamol Overdose Patterns in Australia

Paracetamol poisoning has distinct patterns in Australia:

Demographics:

  • Peak age: 15-35 years
  • Female predominance (intentional overdose)
  • Often associated with alcohol co-ingestion

Therapeutic misadventure:

  • Significant proportion of ALF from staggered/therapeutic overdose
  • Often involves multiple paracetamol-containing products
  • Associated with chronic pain, poor health literacy

Combination products:

  • Paracetamol combined with opioids (codeine, oxycodone)
  • Paracetamol combined with antihistamines (cold preparations)
  • Patients may not recognise paracetamol content

Retrieval and Transfer

Principles:

  • Early contact with liver transplant unit (before meeting KCC)
  • Transfer to transplant centre when Grade II+ HE or meeting KCC
  • Retrieval services: NETS, CareFlight, Adult Retrieval Victoria, RFDS

Pre-transfer stabilisation:

  • Secure airway if Grade III-IV HE
  • Blood glucose management
  • Coagulopathy correction only for active bleeding/procedures
  • NAC continuation if paracetamol
  • ICP management if cerebral oedema suspected

Indigenous Health Considerations

Indigenous Health Context

Aboriginal and Torres Strait Islander Peoples

Epidemiological Considerations:

  • Higher rates of hepatitis B infection (particularly in Northern Australia and remote communities)
  • HBV-related ALF can occur with reactivation during immunosuppression or treatment non-adherence
  • Limited data on paracetamol ALF specifically in Indigenous populations
  • Higher burden of chronic liver disease (alcohol-related, viral) - though these cause ACLF rather than ALF
  • Hepatitis A outbreaks in remote communities (vaccination programs have improved this)

Healthcare Access Challenges:

  • Geographic isolation may delay presentation
  • Limited access to tertiary hepatology/ICU services
  • Transfer to distant liver transplant centres separates patients from family and Country
  • Retrieval logistics in remote areas (RFDS essential)

Cultural Considerations:

  • Family and community involvement in major medical decisions essential
  • Aboriginal Health Workers (AHWs) and Aboriginal Liaison Officers (ALOs) should be involved
  • Cultural protocols around serious illness and potential death
  • Men's and women's business considerations
  • Language interpreters for non-English speakers
  • Understanding of health concepts may differ - use appropriate health literacy approaches
  • "Sorry Business" and cultural obligations may affect family availability
  • Connection to Country important for healing and wellbeing

Transplant Considerations:

  • Relocation to transplant centre (major cities) involves separation from Country and community
  • Long-term immunosuppression adherence challenges
  • Regular follow-up appointments distant from home
  • Support structures (accommodation, transport, family support) crucial
  • Post-transplant care pathways back to community require coordination

Māori Health (New Zealand)

Epidemiological Considerations:

  • Higher rates of viral hepatitis (hepatitis B)
  • May have delayed presentation due to healthcare access barriers
  • Limited data on ALF specifically in Māori population

Cultural Considerations:

  • Whānau (extended family) central to all decision-making - involve early and throughout
  • Kaumātua (elders) may need to be present for major decisions
  • Tikanga Māori (cultural practices) should be respected
  • Te reo Māori (Māori language) services as needed
  • Karakia (prayers/blessings) may be requested
  • Understanding of Māori health models (Te Whare Tapa Whā - holistic wellbeing)
  • Māori Health Workers involvement
  • Manaakitanga (care, hospitality) principles in healthcare delivery

Te Tiriti o Waitangi Obligations:

  • Ensure equitable access to liver transplant services
  • Partnership in care decisions
  • Protection of Māori health outcomes
  • Address systemic barriers to care

SAQ Practice Questions

Clinical Note

Question: Describe the pathophysiology of paracetamol-induced hepatotoxicity, including the mechanisms of hepatocyte death and the concept of hepatic zonality. (15 marks)

Model Answer

1. Introduction and Clinical Context (1 mark)

Paracetamol hepatotoxicity results from the accumulation of a toxic metabolite, NAPQI, when detoxification pathways are overwhelmed. The patient has ingested approximately 25 g of paracetamol, which is a severely hepatotoxic dose (>200 mg/kg).

2. Normal Paracetamol Metabolism (3 marks)

Primary pathways (90%):

  • Glucuronidation via UGT enzymes (55%)
  • Sulfation via SULT enzymes (35%)
  • Both produce non-toxic water-soluble metabolites for renal excretion

Secondary pathway (5-10%):

  • Cytochrome P450 oxidation (primarily CYP2E1, also CYP1A2 and CYP3A4)
  • Produces NAPQI (N-acetyl-p-benzoquinone imine) - a highly reactive, toxic metabolite

Detoxification of NAPQI:

  • NAPQI is rapidly conjugated with glutathione (GSH)
  • Forms non-toxic mercapturic acid for renal excretion
  • Requires adequate hepatic glutathione stores

3. Toxicity in Overdose - NAPQI Accumulation (4 marks)

Phase 1: Glutathione depletion

  • Glucuronidation and sulfation pathways become saturated
  • Increased CYP450 metabolism → more NAPQI generated
  • Glutathione consumed faster than regenerated
  • Critical threshold: >70% GSH depletion

Phase 2: Protein adduct formation

  • Excess NAPQI binds covalently to cellular proteins (cysteine residues)
  • Particularly targets mitochondrial proteins
  • Protein adducts disrupt enzyme function

Phase 3: Mitochondrial dysfunction

  • Impaired electron transport chain (especially Complex I)
  • Decreased ATP production
  • Increased reactive oxygen species (ROS) generation
  • Opening of mitochondrial permeability transition pore (mPTP)

Phase 4: Amplification by JNK

  • ROS activate c-Jun N-terminal kinase (JNK) in cytoplasm
  • Activated JNK translocates to mitochondria
  • JNK amplifies mitochondrial oxidative stress
  • Creates positive feedback loop of injury

4. Mechanisms of Hepatocyte Death (3 marks)

Necrosis (predominant in severe toxicity):

  • ATP depletion prevents active cell death pathways
  • Loss of ion homeostasis (Na⁺/K⁺-ATPase failure)
  • Cellular swelling and membrane rupture
  • Release of DAMPs → sterile inflammation
  • Karyolysis (nuclear dissolution)

Apoptosis (if ATP partially preserved):

  • Cytochrome c release from mitochondria → activates caspase-9
  • Caspase-9 activates caspase-3 (executioner caspase)
  • Controlled cell death with formation of apoptotic bodies
  • Less inflammatory response

Regulated necrosis (necroptosis):

  • RIPK1/RIPK3/MLKL pathway may contribute
  • Programmed necrotic death when caspases inhibited

5. Hepatic Zonality (3 marks)

Liver acinus structure:

  • Functional unit organised around portal triad and central vein
  • Blood flows from Zone 1 (periportal) → Zone 2 → Zone 3 (centrilobular)

Zone 3 (centrilobular) characteristics:

  • Highest CYP2E1 concentration → most NAPQI generated
  • Lowest oxygen tension (venous end of sinusoid) → vulnerable to hypoxia
  • Lowest glutathione levels → least capacity for NAPQI detoxification
  • Lowest NADPH → impaired GSH regeneration

Histological pattern:

  • Centrilobular (Zone 3) necrosis characteristic of paracetamol toxicity
  • May progress to bridging necrosis (Zone 3 to Zone 3) in severe cases
  • Eventually massive/panacinar necrosis in fulminant disease
  • Zone 1 (periportal) relatively spared

6. Clinical Implications (1 mark)

  • N-acetylcysteine (NAC) is the antidote: replenishes glutathione, provides antioxidant effects, supports mitochondrial function
  • Most effective within 8-10 hours but beneficial up to 24+ hours
  • Zone 3 pattern on biopsy confirms paracetamol aetiology
  • Severity of Zone 3 necrosis correlates with clinical severity

Clinical Note

Question: Describe the pathophysiology of hepatic encephalopathy and cerebral oedema in acute liver failure. Explain why ALF patients are at higher risk of cerebral oedema than patients with chronic liver disease. (15 marks)

Model Answer

1. Introduction (1 mark)

Hepatic encephalopathy (HE) in acute liver failure (ALF) represents a neuropsychiatric syndrome caused primarily by hyperammonaemia. Unlike chronic liver disease, ALF carries a high risk of cerebral oedema and intracranial hypertension due to the acute nature of the metabolic insult.

2. Ammonia Metabolism and Accumulation (3 marks)

Normal ammonia handling:

  • Sources: Gut bacteria (urease), enterocyte glutaminase, renal ammoniagenesis, muscle deamination
  • Absorbed from colon into portal circulation
  • 85% cleared by periportal hepatocytes via urea cycle (ornithine transcarbamylase pathway)
  • Remaining ammonia: perivenous hepatocytes convert to glutamine (glutamine synthetase)
  • Normal arterial ammonia: <50 μmol/L

In liver failure:

  • Massive hepatocyte loss → reduced urea cycle capacity
  • Porto-systemic shunting → ammonia bypasses liver
  • Increased renal ammoniagenesis (due to hypokalemia, alkalosis common in ALF)
  • Arterial ammonia rises (this patient: 185 μmol/L - severely elevated)

3. The Ammonia-Glutamine-Astrocyte Swelling Pathway (4 marks)

Step 1: Blood-brain barrier crossing

  • Ammonia exists in equilibrium: NH₃ (un-ionised) ⇌ NH₄⁺ (ionised)
  • Only NH₃ freely crosses the blood-brain barrier
  • Alkalosis favours NH₃ form → increased CNS penetration
  • In ALF, massive systemic ammonia overcomes normal BBB buffering

Step 2: Astrocyte uptake and glutamine synthesis

  • Ammonia enters astrocytes (NOT neurons - neurons lack glutamine synthetase)
  • Glutamine synthetase catalyses: Glutamate + NH₃ → Glutamine
  • This is the ONLY pathway for ammonia detoxification in the CNS
  • Glutamine accumulates within astrocytes

Step 3: Osmotic stress and astrocyte swelling

  • Glutamine is osmotically active
  • Water enters astrocytes → cellular swelling
  • This is CYTOTOXIC oedema (intracellular)
  • Astrocyte swelling is the hallmark of HE in ALF

Step 4: "Trojan horse" mitochondrial toxicity

  • Glutamine transported into astrocyte mitochondria
  • Mitochondrial glutaminase cleaves glutamine → releases ammonia INSIDE mitochondria
  • High intra-mitochondrial ammonia → mPTP opening → oxidative stress
  • Mitochondrial dysfunction → impaired astrocyte energy metabolism
  • Amplifies cellular dysfunction beyond osmotic effects alone

4. Additional Mechanisms of Hepatic Encephalopathy (2 marks)

MechanismContribution
NeuroinflammationSystemic inflammation (SIRS) → microglial activation, BBB dysfunction; synergises with ammonia
GABA-ergic toneIncreased endogenous benzodiazepine-like substances; increased GABA receptor sensitivity
False neurotransmittersAromatic amino acids (phenylalanine, tyrosine, tryptophan) cross BBB; compete with catecholamine synthesis
ManganeseNormally excreted in bile; accumulates in basal ganglia → T1 MRI hyperintensity
Oxidative stressDirect ammonia and inflammatory-mediated neuronal oxidative damage

5. Cerebral Oedema: Cytotoxic vs Vasogenic (3 marks)

Cytotoxic oedema (predominant in ALF):

  • Intracellular fluid accumulation (astrocyte swelling)
  • Blood-brain barrier remains INTACT (at least initially)
  • Mechanism: glutamine accumulation → osmotic stress
  • MRI: Restricted diffusion (DWI bright, ADC dark)
  • Predominantly affects grey matter (astrocyte-rich)

Vasogenic oedema (less prominent initially):

  • Extracellular fluid accumulation
  • Requires BBB breakdown
  • May develop later in severe cases
  • Predominantly affects white matter

In ALF: Primarily cytotoxic mechanism, unlike traumatic brain injury or stroke where vasogenic oedema predominates.

6. Why ALF Has Higher Cerebral Oedema Risk Than Chronic Liver Disease (2 marks)

FactorAcute Liver FailureChronic Liver Disease
Ammonia riseAcute, rapidGradual, chronic
Astrocyte adaptationNo time to adaptAstrocytes develop compensatory mechanisms (osmolyte extrusion)
Glutamine accumulationRapid, overwhelmingChronic low-grade elevation
Inflammatory componentSevere SIRS, acute inflammationLess acute inflammation
Systemic illnessMulti-organ failure, cytokine stormMore stable systemic state
Osmolyte compensationNoneAstrocytes extrude myo-inositol, taurine to maintain volume

Chronic adaptation: In chronic liver disease, astrocytes upregulate volume regulatory mechanisms - they export organic osmolytes (myo-inositol, taurine, glycerophosphocholine) to compensate for glutamine accumulation. This adaptation takes weeks to develop and is absent in ALF.

Clinical significance: Cerebral oedema complicates 20-30% of Grade III-IV HE in ALF but is rare in chronic liver disease. Ammonia >150-200 μmol/L in ALF is a major risk factor for intracranial hypertension and herniation.


Viva Practice Scenarios

Viva Scenario

Stem: "A 38-year-old woman with acute liver failure from paracetamol overdose has an INR of 7.2. The surgical team is concerned about placing a central venous catheter due to bleeding risk."


Examiner: "Tell me about the coagulopathy in acute liver failure."

Candidate: "Acute liver failure causes a complex coagulopathy due to impaired hepatic synthesis. The liver produces virtually all coagulation factors except Factor VIII and von Willebrand factor, which are produced by endothelium.

The procoagulant factors with shortest half-lives are affected earliest:

  • Factor VII has a half-life of only 4-6 hours, explaining why INR rises rapidly
  • Factor II (prothrombin), V, IX, and X are also reduced
  • Fibrinogen may be normal initially due to the acute phase response

However, I would emphasise that the coagulopathy in ALF is more complex than simple factor deficiency..."


Examiner: "Go on - what do you mean by 'more complex'?"

Candidate: "The concept of 'rebalanced haemostasis' is now recognised as crucial to understanding coagulation in liver failure.

The liver also synthesises the major anticoagulant proteins:

  • Protein C (half-life 8 hours) - often profoundly reduced
  • Protein S
  • Antithrombin

The INR measures ONLY the procoagulant pathway. It does not reflect the parallel reduction in anticoagulants.

Studies using thrombin generation assays and thromboelastography have shown that:

  • Global haemostasis may be NORMAL or even pro-thrombotic
  • The INR does NOT accurately predict bleeding risk in liver failure
  • Patients may be at risk of both bleeding AND thrombosis

The haemostatic balance is precarious - additional insults such as sepsis, renal failure, or procedures can tip the balance in either direction."


Examiner: "So should we give FFP to this patient before central line insertion?"

Candidate: "This is a nuanced decision. Current evidence suggests that routine FFP administration to 'correct' the INR is not indicated for several reasons:

  1. The INR may not reflect true bleeding risk
  2. FFP provides both procoagulant AND anticoagulant factors, potentially not changing the balance
  3. FFP has risks: volume overload, transfusion reactions, TRALI, loss of prognostic information from INR

However, for invasive procedures, many clinicians take a pragmatic approach:

  • Consider thromboelastography (TEG/ROTEM) for better assessment of global haemostasis
  • Target INR <1.5-2.0 with FFP if TEG suggests coagulopathy
  • Use ultrasound guidance to minimise complications
  • Consider internal jugular rather than subclavian (compressible if bleeding)

For this patient requiring a CVC, I would:

  1. Obtain TEG to assess global haemostasis
  2. Use ultrasound-guided IJ access
  3. Consider FFP only if TEG shows prolonged clot formation time
  4. Avoid transfusing to an arbitrary INR target"

Examiner: "What about VTE prophylaxis in this patient?"

Candidate: "This is another area where the concept of rebalanced haemostasis is clinically important.

Despite elevated INR, patients with ALF may not be protected from venous thromboembolism:

  • Reduced anticoagulants (Protein C, S, Antithrombin)
  • Elevated vWF (endothelial activation, reduced ADAMTS13)
  • Reduced mobility, central lines, inflammation - all VTE risk factors

Current practice varies, but many experts recommend:

  • Mechanical prophylaxis (graduated compression stockings, pneumatic devices) for all patients
  • Pharmacological prophylaxis (LMWH or UFH) can be considered if not actively bleeding
  • Assess on individual basis using TEG if available

The key message is that high INR does not equate to 'auto-anticoagulation' in liver failure."


Examiner: "Excellent. Finally, tell me about Factor V levels in ALF."

Candidate: "Factor V has special significance in ALF for several reasons:

  1. It is synthesised EXCLUSIVELY by the liver (unlike Factor VIII which is endothelial)
  2. It has an intermediate half-life (12-24 hours)
  3. It is consumed in DIC, which often complicates ALF

Factor V level <20% is a very poor prognostic marker, reflecting severe synthetic failure. It is used in the Clichy criteria (French prognostic model) for transplant listing.

Factor V is valuable because:

  • It reflects both production (hepatocyte mass) and consumption (DIC)
  • It is not affected by vitamin K administration (unlike factors II, VII, IX, X)
  • Serial measurement may track disease progression or recovery

In this patient with paracetamol ALF, a very low Factor V would suggest severe hepatocyte loss and poor prognosis without transplantation."


Viva Scenario

Stem: "A 45-year-old man with acute liver failure (subacute, drug-induced) develops oliguria on day 5 of ICU admission. Creatinine has risen from 95 to 280 μmol/L over 48 hours. Urinalysis is bland."


Examiner: "What is the differential diagnosis for acute kidney injury in this patient with acute liver failure?"

Candidate: "The differential for AKI in the context of acute liver failure includes:

  1. Hepatorenal syndrome (HRS): Functional renal failure due to splanchnic vasodilation and compensatory renal vasoconstriction - the most concerning diagnosis

  2. Pre-renal azotaemia: True volume depletion from:

    • GI losses, reduced intake
    • Third-spacing (ascites, oedema)
    • Haemorrhage
  3. Acute tubular necrosis (ATN): From:

    • Hypotension/shock
    • Nephrotoxins (in paracetamol ALF, NAPQI metabolites may be directly nephrotoxic)
    • Sepsis
  4. Abdominal compartment syndrome: Raised intra-abdominal pressure from ascites/ileus causing renal venous congestion

  5. Nephrotoxic drugs: NSAIDs, aminoglycosides, contrast

The bland urinalysis (no casts, minimal proteinuria) suggests either pre-renal or HRS rather than ATN."


Examiner: "Explain the pathophysiology of hepatorenal syndrome."

Candidate: "Hepatorenal syndrome is explained by the 'arterial vasodilation hypothesis':

Stage 1: Splanchnic Vasodilation

  • Portal hypertension (even acute) leads to splanchnic NO and prostacyclin release
  • Marked vasodilation of the mesenteric arterial bed
  • Blood 'pools' in the splanchnic circulation
  • Reduced effective arterial blood volume (EABV) despite normal or increased total blood volume

Stage 2: Compensatory Neurohormonal Activation

  • Arterial baroreceptors sense reduced EABV
  • Massive activation of:
    • Renin-angiotensin-aldosterone system (RAAS)
    • Sympathetic nervous system
    • Arginine vasopressin (ADH)

Stage 3: Renal Vasoconstriction

  • Angiotensin II, noradrenaline, and ADH cause profound renal arterial vasoconstriction
  • Reduced renal blood flow and GFR
  • Kidneys are structurally NORMAL - the failure is purely functional

Stage 4: Progressive Decompensation

  • Eventually cardiac output fails to compensate for peripheral vasodilation
  • Worsening effective hypovolaemia despite salt and water retention
  • Progressive renal hypoperfusion

The key point is that HRS represents a maldistribution of blood flow - excessive splanchnic vasodilation with compensatory renal vasoconstriction - rather than primary kidney disease."


Examiner: "How would you diagnose HRS in this patient?"

Candidate: "The International Club of Ascites (ICA) 2015 criteria for HRS diagnosis are:

  1. Cirrhosis with ascites OR acute liver failure - our patient has ALF

  2. Diagnosis of AKI: Increase in creatinine ≥26.5 μmol/L within 48 hours OR ≥50% increase within 7 days - this patient meets criteria (185 μmol/L rise)

  3. No improvement after:

    • Withdrawal of diuretics (if any)
    • Plasma volume expansion with albumin 1 g/kg/day for 2 days (maximum 100 g/day)
  4. Absence of shock at time of diagnosis

  5. No current or recent nephrotoxic medications

  6. No parenchymal kidney disease:

    • Proteinuria <500 mg/day
    • Microhaematuria <50 RBCs per high-power field
    • Normal renal ultrasound

For this patient, I would:

  • Review medication chart for nephrotoxins
  • Ensure adequate volume status (CVP or dynamic assessment)
  • Trial albumin expansion
  • Check urinalysis and urine microscopy
  • Perform renal ultrasound
  • Calculate FENa (expected <1% in HRS, >2% in ATN)

If creatinine does not improve after albumin trial and other criteria are met, HRS is likely."


Examiner: "Is HRS in acute liver failure the same as in cirrhosis?"

Candidate: "There are important differences between HRS in ALF versus cirrhosis:

FeatureHRS in ALFHRS in Cirrhosis
Portal hypertensionAcute, less establishedChronic, severe
AscitesOften mild or absentUsually prominent
Mechanism emphasisSystemic inflammation (SIRS) plays larger roleSplanchnic vasodilation dominant
Nephrotoxic factorsMay have ATN component (e.g., paracetamol metabolites)More purely functional
ReversibilityMay reverse if liver recovers/transplantedRarely reverses without transplant
PharmacotherapyLimited evidence for terlipressin in ALFTerlipressin + albumin evidence in cirrhosis

In ALF, renal failure often has multiple contributing factors - the SIRS response, potential direct nephrotoxicity, and the HRS mechanism all contribute. Recovery of liver function (spontaneously or post-transplant) typically leads to renal recovery, supporting the functional nature.

Treatment options include:

  • Supportive care and optimise volume status
  • Terlipressin + albumin (extrapolated from cirrhosis data)
  • Noradrenaline + albumin (alternative vasoconstrictor)
  • Renal replacement therapy if severe
  • Liver transplantation - definitive treatment (kidneys usually recover post-transplant)"

MCQ Practice Questions

Question 1

A 28-year-old woman presents 18 hours after ingesting 40 paracetamol tablets. Which zone of the hepatic acinus is most susceptible to paracetamol-induced necrosis?

A. Zone 1 (periportal) B. Zone 2 (intermediate) C. Zone 3 (centrilobular) D. All zones equally affected E. Zone 1 and Zone 2 equally

Answer: C

Explanation: Zone 3 (centrilobular/perivenular) is most susceptible to paracetamol toxicity for several reasons: (1) Highest concentration of CYP2E1, the primary enzyme converting paracetamol to the toxic metabolite NAPQI; (2) Lowest oxygen tension as blood flows from portal (Zone 1) to central (Zone 3); (3) Lowest glutathione levels, reducing capacity to detoxify NAPQI. Histologically, paracetamol overdose shows centrilobular necrosis. Zone 1 is preferentially damaged by phosphorus poisoning. This zonality is a classic CICM First Part concept.


Question 2

Which of the following statements about coagulopathy in acute liver failure is CORRECT?

A. INR accurately predicts bleeding risk in ALF B. Protein C levels are typically preserved while procoagulant factors decrease C. Prophylactic FFP should be given to all patients with INR >2.0 D. Thromboelastography provides better assessment of global haemostasis than INR E. VTE prophylaxis is contraindicated when INR >2.0

Answer: D

Explanation: Thromboelastography (TEG/ROTEM) provides a better assessment of global haemostasis in ALF because it measures the entire coagulation process, including the contribution of both procoagulant and anticoagulant factors. The concept of "rebalanced haemostasis" recognises that INR only measures procoagulant factor reduction, not the parallel reduction in Protein C, Protein S, and Antithrombin. Studies show INR does not accurately predict bleeding risk in liver failure. Routine prophylactic FFP is not recommended. VTE prophylaxis may be appropriate despite elevated INR as patients are not "auto-anticoagulated."


Question 3

In the pathophysiology of hepatic encephalopathy, which cell type is primarily responsible for ammonia detoxification in the central nervous system?

A. Neurons B. Astrocytes C. Microglia D. Oligodendrocytes E. Ependymal cells

Answer: B

Explanation: Astrocytes are the only CNS cells that express glutamine synthetase, the enzyme that converts ammonia and glutamate to glutamine. This is the exclusive pathway for ammonia detoxification in the brain. The accumulation of glutamine within astrocytes creates osmotic stress, leading to astrocyte swelling - the hallmark of hepatic encephalopathy in ALF (cytotoxic oedema). Neurons do NOT have this enzyme and are not directly involved in ammonia metabolism. The "Trojan horse" hypothesis describes how glutamine subsequently enters mitochondria where it releases ammonia, causing further damage.


Question 4

A patient with acute liver failure has Grade IV hepatic encephalopathy. CT brain shows cerebral oedema. Which type of cerebral oedema predominates in acute liver failure?

A. Vasogenic oedema B. Cytotoxic oedema C. Interstitial (hydrocephalic) oedema D. Osmotic oedema E. Mixed vasogenic and interstitial

Answer: B

Explanation: Cerebral oedema in ALF is predominantly CYTOTOXIC (intracellular), caused by astrocyte swelling from glutamine accumulation. The blood-brain barrier remains largely intact, at least initially. This differs from traumatic brain injury or tumours where vasogenic oedema (extracellular, BBB breakdown) predominates. On MRI, cytotoxic oedema shows restricted diffusion (DWI bright, ADC dark). This is why ALF patients are at high risk of cerebral oedema while chronic liver disease patients (who develop compensatory mechanisms) rarely develop significant oedema despite similar ammonia levels.


Question 5

According to the King's College Criteria for paracetamol-induced acute liver failure, which single finding indicates poor prognosis and need for transplant assessment?

A. INR >3.5 B. Bilirubin >300 μmol/L C. pH <7.30 after adequate fluid resuscitation D. Creatinine >200 μmol/L E. Grade II hepatic encephalopathy

Answer: C

Explanation: For paracetamol-induced ALF, pH <7.30 ALONE (after adequate fluid resuscitation) meets King's College Criteria for poor prognosis. Alternatively, ALL THREE of the following are required: INR >6.5 (not 3.5) AND Creatinine >300 μmol/L (not 200) AND Grade III-IV encephalopathy (not Grade II). The pH <7.30 criterion has the strongest predictive value as it reflects severe metabolic acidosis from massive hepatocyte necrosis and lactate accumulation. INR >3.5 and bilirubin >300 are criteria for NON-paracetamol ALF, not paracetamol.